Skip to main content

Table 3 Fasting plasma insulin and incidence of AF analysed with competing risks regression considering mortality as a competing event

From: Low fasting plasma insulin is associated with atrial fibrillation in men from a cohort study - the Malmö preventive project

   Model 1 Model 2
   SHR 95% CI P SHR 95% CI P
Both genders Ln-Insulin 0.81 0.74-0.88 <.0001 0.80 0.73-0.88 <.0001
Quartile 1 reference      
Quartile 2 0.99 0.83-1.18 .89 0.99 0.83-1.17 .89
Quartile 3 0.78 0.65-0.94 0.008 0.78 0.64-0.93 0.007
Quartile 4 0.69 0.57-0.84 <.0001 0.69 0.57-0.83 <.0001
Men Ln-Insulin 0.80 0.73-0.88 <.0001 0.80 0.72-0.87 <.0001
Quartile 1 reference      
Quartile 2 0.95 0.79-1.14 0.59 0.95 0.80-1.14 0.60
Quartile 3 0.75 0.62-0.92 0.005 0.75 0.62-0.92 0.005
Quartile 4 0.66 0.54-0.81 <.0001 0.65 0.53-0.80 <.0001
Women Ln-Insulin 0.89 0.69-1.15 0.39 0.87 0.68-1.13 0.31
Quartile 1 reference      
Quartile 2 1.25 0.68-2.31 0.47 1.22 0.66-2.26 0.52
Quartile 3 0.94 0.57-1.57 0.82 0.94 0.56-1.57 0.82
Quartile 4 1.02 0.61-1.70 0.93 0.98 0.59-1.64 0.95
  1. Based on 7066 individuals (6052 men and 1014 women) and 983 cases. Model 1 is adjusted for age, sex (where applicable), height and weight. Model 2 is adjusted for Model 1 covariates + systolic blood pressure and smoking status. SHR for ln-Insulin is expressed per log unit. SHR = sub-hazards ratio from a competing risk regression.